An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial-MedSci.cn

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial

Gelsomino, F; Tiseo, M; Boni, L; Cavanna, L; Camerini, A; Chiari, R; Verusio, C; Tognetto, M; Ardizzoni, A

ANNALS OF ONCOLOGY, 2019; 30 ():

科室
- - 订阅+
  - 更多科室
工具
服务